2020 Volume 37 Issue 5 Pages 723-727
Recent advances and new findings relating to multiple sclerosis (MS) and other inflammatory disorders in the central nervous system were reviewed. The following topics were discussed : the significance of silent progression in disability progression of MS, the association between the initial disease modifying therapies and the risk of developing secondary progressive MS, the risk of progressive multifocal leukoencephalopathy in MS patients receiving extended interval dosing of natalizumab, the efficacy and safety of three randomized controlled trials of novel biotherapies for relapse prevention of neuromyelitis optica spectrum disorder, such as eculizumab (anti–complement therapy), inebilizumab (B–cell depleting therapy), and satralizumab (interleukin–6/interleukin–6 receptor axis blockage therapy), and the relapse prevention therapy for myelin oligodendrocyte glycoprotein antibody–associated disease.
